U.S. Markets open in 3 hrs 28 mins

Cassava Sciences, Inc. (SAVA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
77.63-12.09 (-13.48%)
At close: 4:00PM EDT
79.80 +2.17 (2.80%)
Pre-Market: 05:56AM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close89.72
Open88.43
Bid77.63 x 1300
Ask81.17 x 1100
Day's Range72.48 - 89.08
52 Week Range2.61 - 117.54
Volume6,482,255
Avg. Volume1,762,846
Market Cap3.106B
Beta (5Y Monthly)1.17
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateDec 13, 2012
1y Target EstN/A
  • Cassava Sciences Selects Clinical Research Organization for Phase 3 Clinical Program in Alzheimer’s Disease
    GlobeNewswire

    Cassava Sciences Selects Clinical Research Organization for Phase 3 Clinical Program in Alzheimer’s Disease

    Selection of Premier Research as CRO Marks Significant Milestone Toward Initiation of Phase 3 Program of Simufilam in Alzheimer’s DiseaseAUSTIN, Texas, June 21, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced the selection of Premier Research International as its clinical research organization (CRO) to help conduct the Phase 3 clinical program of simufilam for Alzheimer’s disease. Consistent with previous gui

  • Cassava Sciences Provides Mid-Year Corporate Update, Clinical Development Progress and Announces Guidance on Clinical Data Release
    GlobeNewswire

    Cassava Sciences Provides Mid-Year Corporate Update, Clinical Development Progress and Announces Guidance on Clinical Data Release

    Open-label Study Completes Patient EnrollmentCognition Maintenance Study Initiated May 2020, now 30% Enrolled6-month Biomarker Data to be Presented at AAIC Conference in July9-month Safety & Cognition Data to be Presented at AAIC Conference Clinical Results with SavaDx to be Presented at AAIC ConferencePhase 3 Program Initiation Remains On-track for 2nd Half 2021 AUSTIN, Texas, June 21, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s

  • Cassava Sciences to Present at the Raymond James 2021 Human Health Innovation Conference
    GlobeNewswire

    Cassava Sciences to Present at the Raymond James 2021 Human Health Innovation Conference

    AUSTIN, Texas, June 17, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it has been invited to present at the Raymond James 2021 Human Health Innovation Conference, a virtual event taking place on June 21-23, 2021. Remi Barbier, President & CEO, and Eric Schoen, Chief Financial Officer, will present a corporate overview on Tuesday, June 22nd at 3:20pm Eastern time. Management will also hos